Physician profile
Christopher Rittman
NPI 1235281767
$1,103.76
in general payments reported to CMS, 2019-2025
17 companies · $262 in 2025
The $262 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76.56 · 2020: $109 · 2021: $138 · 2022: $200 · 2023: $196 · 2024: $122 · 2025: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $580.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $580.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $406.77 | 2019-2025 | Ozempic |
| Pfizer INC. | $125.00 | 2023 | |
| Lilly USA, LLC | $106.49 | 2020-2024 | Mounjaro |
| Abbvie INC. | $69.10 | 2021-2023 | Ubrelvy, Vraylar |
| Merck Sharp & Dohme LLC | $57.12 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.34 | 2022-2025 | Trintellix |
| Jazz Pharmaceuticals INC. | $45.52 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.54 | 2022 | |
| Janssen Pharmaceuticals, INC | $36.89 | 2022-2025 | Spravato |
| Bridgebio Pharma, INC. | $30.49 | 2025 | Attruby |
| Exact Sciences Corporation | $27.79 | 2023-2025 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $27.19 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $21.29 | 2024 | Fasenra |
| Amgen INC. | $18.79 | 2024 | Otezla, Repatha |
| Upsher-Smith Laboratories LLC | $15.15 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $12.89 | 2021 | |
| Allergan, INC. | $12.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Rittman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.